Boehringer Cashes In Co-Marketed Empagliflozin Brands Ahead Of India Patent Expiry

Boehringer Ingelheim’s sale of three diabetes brands in India, with the same composition as Jardiance, Jardiance Met and Glyxambi, to Torrent comes ahead of the expiry of the Indian patent for empagliflozin. A launch for other indications is also expected.